Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
See detailÉtude cartographique et projet de restauration sur une rivière rectifiée, l’Eau Blanche
Peeters, Alexandre ULg; Verniers, Gisèle; Hallot, Eric ULg et al

Conference (2010, October 04)

Detailed reference viewed: 38 (10 ULg)
Full Text
See detailEtude chémo-écologique et comportementale du parasitoïde, Nasonia vitripennis Walker (Hym., Pteromalidae), en vue de son utilisation comme biodétecteur en entomologie forensique
Frederickx, Christine ULg

Doctoral thesis (2012)

Most reports published in the field of forensic entomology are focused on Diptera, mostly on Calliphoridae. However, Hymenoptera are part of the entomofaunal colonisation of a dead body. Despite their ... [more ▼]

Most reports published in the field of forensic entomology are focused on Diptera, mostly on Calliphoridae. However, Hymenoptera are part of the entomofaunal colonisation of a dead body. Despite their significant presence in crime scenes, parasitoids are largely ignored due to their small size and the paucity of biological and behavioral information available in the ecosystem of corpse. The use of Hymenoptera parasitoids in forensic entomology can be relevant to many applications such as development of a biodectector. The objectives of this thesis were (1) to identify the Hymenoptera community parasitizing necrophagous Diptera, (2) to identify volatile organic compounds emitted by decaying process and by hosts which facilitate host-habitat and host location by female Nasonia vitripennis Walker (3) to evaluate the species N. vitripennis as biodectector of corpses. The faunistic study has identified five species of Hymenoptera in cadaver ecosystem. Alysia manducator was the most abundant Braconidae species. However, N. vitripennis was chosen as insect model; because over the last 50 years, this wasp has been intensely investigated in the subject of genetic, ecological and evolutionary research. A chemo-ecological approach, combining EAG and behavioral studies, was used on N. vitripennis with selected compounds from the decay process and their hosts. Firstly, we have demonstrated that host- habitat location and host location were dependent on the concentration of volatile organic compounds tested. In addition, dimethyldisulfide, a key component of decomposition and also released by Calliphora vicina Robineau-Desvoidy (Diptera, Calliphoridae) pupae, has a biological activity. Secondly, we have showed that rate of parasitism was based on the age of pupa, depth and substrate in which larvae burrow. This rate is the most important when pupae were six day-old, on the surface of soil and in a soil with a granulometry greater than 1mm. Moreover, N. vitripennis expanded our potential resource in biosensor used in forensic science. Females demonstrated a capacity for learning and memory. [less ▲]

Detailed reference viewed: 68 (15 ULg)
Full Text
Peer Reviewed
See detailEtude chimiotaxonomique dans les genres Macrotyloma, Dolichos et Pseudovigna
Dardenne, G. A.; Thonart, Philippe ULg; Otoul, E. et al

in Phytochemistry (1972), 12

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailEtude chimique de la graine de Simarouba glauca D.C. Détermination de la structure des triglycérides
Lognay, Georges ULg; Ergo, A.; Wathelet, Jean-Paul ULg et al

in Revue Française des Corps Gras (1981), 3

Une étude détatllée sur I'amande de la graine de Simarouba glauca D.C. est présentée. Cet arbuste tropical originarre d'Amérique Centrale est implanté depuis quelques années au Burundi. La graine est ... [more ▼]

Une étude détatllée sur I'amande de la graine de Simarouba glauca D.C. est présentée. Cet arbuste tropical originarre d'Amérique Centrale est implanté depuis quelques années au Burundi. La graine est analysée et deux modes d'extraction des lipides totaux sont testés. Les paramètres caractérisant la matière grasse sont déterminés, L'analyse des triglycérides et la détermination de leur structure sont entrcprises suivant les méthodes de calcul proposées par Van Der Wal et par Wathelet. Des pourcentages élevés en 00St - 000 - StOSt - POSt - OOP sont rencontrés et les principaux triglycérides sont du type mono-insaturé symétrique (SlS), di-insaturé asymetrique (SII) et tri-insaturé (III). [less ▲]

Detailed reference viewed: 70 (4 ULg)
Full Text
See detailEtude chromatographique de substances volatiles : cas des sémiochimiques
Heuskin, Stéphanie ULg

Scientific conference (2007, October)

Detailed reference viewed: 1 (0 ULg)
Full Text
See detailEtude chromatographique de substances volatiles : cas des sémiochimiques
Heuskin, Stéphanie ULg

Scientific conference (2008, December)

Detailed reference viewed: 4 (0 ULg)
Full Text
See detailEtude chromatographique de substances volatiles : cas des sémiochimiques
Heuskin, Stéphanie ULg

Scientific conference (2009, November)

Detailed reference viewed: 11 (2 ULg)
Full Text
See detailEtude chromatographique de substances volatiles : cas des sémiochimiques
Heuskin, Stéphanie ULg

Scientific conference (2010, November)

Detailed reference viewed: 3 (0 ULg)
Full Text
See detailEtude chromatographique de substances volatiles: cas des sémiochimiques
Heuskin, Stéphanie ULg

Scientific conference (2009, November 10)

Detailed reference viewed: 43 (15 ULg)
See detailEtude cinématographique de la marche de l'hémiplégique : Intérêt de l'électrostimulation fonctionnelle
Vanderthommen, Marc ULg; Bauval, A.; Croisier, Jean-Louis ULg et al

in Actualités en Rééducation Fonctionnelle et Réadaptation, 20ème série (1995)

Detailed reference viewed: 47 (1 ULg)
Full Text
See detailÉtude climatologique des irrégularités ionosphériques détectées à l'aide des GNSS
Wautelet, Gilles ULg

Master of advanced studies dissertation (2007)

Detailed reference viewed: 48 (12 ULg)
Full Text
Peer Reviewed
See detailEtude clinique comparative de l'effet de la prostaglandine F2alpha sur la rétention placentaire chez la vache
Hanzen, Christian ULg; Baudoux, Ch

in Annales de Médecine Vétérinaire (1985), 129

Detailed reference viewed: 58 (8 ULg)
Full Text
Peer Reviewed
See detailEtude clinique d’une dyade, régressant en fonctionnement borderline au niveau contextuel, individuel et familial, caractérisée par un passage à l’acte abusif d’ordre sexuel
Aubinet, Suzanne ULg; D'Amore, Salvatore ULg; Cancrini, Luigi

in Thérapie Familiale (2013), 2

This research is based on Luigi Cancrini’s theory of regression in borderline functioning which provides a structured and nuanced reflection on sexual abuse. It offers the possibility of establishing a ... [more ▼]

This research is based on Luigi Cancrini’s theory of regression in borderline functioning which provides a structured and nuanced reflection on sexual abuse. It offers the possibility of establishing a framework for observation and analysis of both synchronic and diachronic blendings; the behavioral characteristics proposed by the victims, perpetrators and their families; and the historical sense that can give them. It leads to the identification of the central link connecting the actors and their life contexts. We analyze a clinical situation with sexual abuse. The chosen dyad, composed by a 7 year-old-girl and a 13 ½ year-old-boy, was observed in vivo during hospitalization. Relevant behavioral, relational and historical components were compiled in an analytic scale based on Cancrini (2009) and Barudy (1997) writings. Similar psychopathological functioning among perpetrators, victims and families could thus be seen within this framework. The comparison of the systems reported similar family dynamics within the different subsystems. For these children, this results in the emergence of a specific behavioral repertory, typical of a borderline functioning, characterizing both the perpetrator and the aggressed: both are embedded in rigid supporting dyadic relational patterns and intense cleaved positions, which are also found within the various systems and the individuals within them. [less ▲]

Detailed reference viewed: 142 (18 ULg)
Full Text
Peer Reviewed
See detailL'etude clinique du mois Quel antihypertenseur en premiere intention? Resultats de l'etude ALLHAT.
Scheen, André ULg; Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (2003), 58(1), 47-52

Antihypertensive therapy is well established to reduce hypertension-related morbidity and mortality, but the optimal first-step therapy is still controversial. The "Antihypertensive and Lipid-Lowering ... [more ▼]

Antihypertensive therapy is well established to reduce hypertension-related morbidity and mortality, but the optimal first-step therapy is still controversial. The "Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial" (ALLHAT) should give such an answer. It is a randomised, double-blind, trial designed to determine whether treatment with either a calcium channel blocker or an angiotensin-converting enzyme inhibitor lowers the incidence of coronary heart disease (CHD) or other cardiovascular disease (CVD) events vs treatment with a diuretic. A total of 33,357 participants aged 55 years or older with mild to moderate hypertension and at least 1 other CHD risk factor were randomly assigned to receive chlorthalidone (12.5 to 25 mg/day; n = 15,255), amlodipine (2.5 to 10 mg/day; n = 9,048) or lisinopril (10 to 40 mg; n = 9,054). The primary outcome combined both fatal CHD and non-fatal myocardial infarction, analyzed by intent-to-treat. Secondary outcomes were all-causes mortality, stroke, combined CHD (primary outcome, coronary revascularization, or angina with hospitalization), and combined CVD (combined CHD, stroke, treated angina without hospitalization, heart failure and peripheral arterial disease). Chlorthalidone was slightly more effective in reducing systolic pressure while amlodipine reduced slightly more effectively diastolic blood pressure. After a mean follow up of 4.9 years, no differences were observed between the three treatments regarding both the primary outcome and the total mortality. Secondary outcomes were similar when comparing amlodipine vs chlorthalidone. A moderately higher 6-year incidence rate of clinically detected heart failure was observed with amlodipine, but without significant influence on mortality. For lisinopril vs chlorthalidone, lisinopril had slightly higher 6-year rates of combined CVD, stroke and heart failure. In conclusion, thiazide-type diuretics are superior in preventing one or more major forms of CVD and offer the advantage to be cheaper. They should be preferred for first-step antihypertensive therapy. However, to reach the recommended blood pressure target, most patients should receive a combination of antihypertensive compounds. Such a combination should always comprise a diuretic agent, in absence of contra-indications. [less ▲]

Detailed reference viewed: 311 (0 ULg)
Full Text
Peer Reviewed
See detailL’ÉTUDE CLINIQUE DU MOIS TECOS : confirmation de la sécurité cardiovasculaire de la sitagliptine
SCHEEN, André ULg; PAQUOT, Nicolas ULg

in Revue Médicale de Liège (2015), 70

Summary : The cardiovascular safety of sitagliptin has been evaluated in TECOS («Trial Evaluating Cardiovascular Outcomes with Sitagliptin»). TECOS recruited patients with type 2 diabetes and a history of ... [more ▼]

Summary : The cardiovascular safety of sitagliptin has been evaluated in TECOS («Trial Evaluating Cardiovascular Outcomes with Sitagliptin»). TECOS recruited patients with type 2 diabetes and a history of cardiovascular disease who received, as add-on to their usual therapy, either sitagliptin (n = 7.257) or placebo (n = 7.266), with a median follow-up of 3 years. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95 % confidence interval, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95 % CI, 0.83 to 1.20; P=0.98). The cardiovascular safety of sitagliptin, which was already shown in meta-analyses of phase II-III randomised controlled trials and in observational cohort studies in real life, is now confirmed in the landmark prospective cardiovascular outcome study TECOS. [less ▲]

Detailed reference viewed: 37 (1 ULg)
Full Text
Peer Reviewed
See detailL'etude clinique du mois. ACCORD-LIPID et ACCORD-EYE: vers un nouveau positionnement du fenofibrate chez le patient diabetique de type 2.
Scheen, André ULg; Van Gaal, L. F.

in Revue Médicale de Liège (2010), 65(9), 533-9

Fenofibrate has been evaluated in the ACCORD trial, in combination with a statin, to prevent vascular complications in patients with type 2 diabetes. In ACCORD-Lipid, the addition of fenofibrate was not ... [more ▼]

Fenofibrate has been evaluated in the ACCORD trial, in combination with a statin, to prevent vascular complications in patients with type 2 diabetes. In ACCORD-Lipid, the addition of fenofibrate was not able to significantly reduce the incidence of a composite cardiovascular endpoint (no positive effect was also observed with the intensification of blood glucose or blood pressure control in this population). However, an interaction effect was observed according to basal lipid profile, suggesting a better protection by fenofibrate in patients with hypertriglyceridaemia and low HDL cholesterol (so-called atherogenic dyslipidaemia). In ACCORD-Eye, the addition of fenofibrate to a basal statin therapy resulted in a significant reduction of the progression of diabetic retinopathy, in a similar manner as that observed with intensifying blood glucose control (but with a good safety profile and without increasing the risk of hypoglycaemia). These observations, confirming earlier results from FIELD also with this fibrate, open new perspectives for a useful prescription of fenofibrate in patients with type 2 diabetes. [less ▲]

Detailed reference viewed: 74 (3 ULg)
Full Text
Peer Reviewed
See detailL'etude clinique du mois. ADVANCE: amelioration de la survie et reduction des complications vasculaires et renales avec la combinaison fixe perindopril-indapamide chez le patient diabetique de type 2.
Scheen, André ULg; Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (2007), 62(10), 639-43

The controlled ADVANCE trial compared the incidence of major macrovascular and microvascular complications in 5,569 type 2 diabetic patients randomised to a fixed combination of perindopril and indapamide ... [more ▼]

The controlled ADVANCE trial compared the incidence of major macrovascular and microvascular complications in 5,569 type 2 diabetic patients randomised to a fixed combination of perindopril and indapamide and in 5,571 patients randomised to placebo, followed for a mean duration of 4.3 years. Compared with patients assigned placebo, those assigned active therapy had a mean reduction in systolic blood pressure of 5.6 mm Hg and diastolic blood pressure of 2.2 mm Hg, despite the fact physicians were allowed to adjust antihypertensive therapy ad libitum. The relative risk of a major macrovascular and microvascular event (primary endpoint) was reduced by 9% (p = 0.041) in the active group. The separate reductions in macrovascular and microvascular events were similar but were not independently statistically significant. The relative risk of death was significantly reduced by 14% (p = 0.025), essentially due to a lower death rate from cardiovascular diseases (-18%; p = 0.027). The incidence of any coronary event was also significantly reduced (-14 %; p = 0.020), while only a trend was observed for all cerebrovascular events. Finally, renal events were significantly less frequent (-21%; p < 0.0001) whereas all ocular events were only slightly reduced (-5%; NS) in the active group as compared to the placebo group. The fixed combination of perindopril and indapamide was well tolerated and easy to administer. Overall one death due to any cause would be averted among every 79 diabetic patients assigned active therapy for 5 years. There was no evidence that the effects of the study treatment differed by initial blood pressure level or concomitant use of other treatments at baseline. [less ▲]

Detailed reference viewed: 238 (7 ULg)